Genentech Announces Plans To Expand Hillsboro Facility
![](/46/pdcnewsitem/03/43/41/CTIuqaoSkKeGYX2.jpg)
Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for the expansion of its fill/finish facility in Hillsboro, Oregon. "This investment in our sterile production operations will result in the addition of up to 100 new skilled manufacturing jobs in the greater Portland area over the next 5 years, potentially bringing the total number of Genentech jobs in Oregon to over 500," said Larry Sanders, General Manager and Vice President, Hillsboro Technical Operations.
"This announcement is another indicator that this is an exciting time in Oregon’s history," said Governor Kate Brown. "Genentech’s investment in its Hillsboro campus and Oregon’s robust workforce underscore that Oregon is a great place for all businesses to build their future and for the biotech sector to grow."
Genentech opened operations in Hillsboro in April 2010. The site is home to a fill/finish facility and warehousing and distribution center. Genentech's product pipeline is among the strongest in the biotechnology and pharmaceutical industries, and demand for its marketed products continues to grow. The expansion of operations at the Hillsboro site is part of the company’s strategy to increase manufacturing capacity to meet that demand.
"Genentech’s plan to expand its Hillsboro facility represents an important milestone in the industry’s growth trajectory in Oregon. Combined with other recent achievements suc as the historic Knight Cancer Challenge, Oregon is positioned to significantly expand our life sciences manufacturing footprint," said Dennis McNannay, Executive Director of the Oregon Bioscience Association.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance